Emisphere Technologies Introduces First Commercially Available Product, Oral Eligen® B12

Life Extension® chosen as a distribution partner for Emisphere`s proprietary
formulation of Vitamin B12
CEDAR KNOLLS, N.J.--(Business Wire)--
Emisphere Technologies, Inc. (OTC BB: EMIS) today announced that the Company is
introducing and launching its first commercially available product, oral Eligen®
B12 (100 mcg). Oral Eligen® B12 (100 mcg) has been specifically developed to
help improve Vitamin B12 absorption and bioavailability with a patented
formulation.

"We are very excited that our first product introduction will help to advance
the field of nutrition by offering a superior oral formulation to improve
Vitamin B12 absorption and bioavailability," says Michael V. Novinski, President
and Chief Executive Officer, Emisphere Technologies. "By partnering with Life
Extension, a highly respected company in the nutrient and supplement field, we
are confident that we will have the proper marketing and sales infrastructure to
allow oral Eligen® B12 (100 mcg) to be successful."

In a trial with healthy subjects conducted last year, Eligen® B12 (100 mcg)
resulted in a ten-fold increase in peak serum B12 blood levels, a two fold
improvement in total bioavailability and a reduction in absorption time greater
than 90% as compared to standard oral commercial formulations.

"Oral Eligen® B12 (100 mcg) is a scientific breakthrough that will help many
individuals by increasing Vitamin B12 levels in the body," notes Dr. Michael
Rothkopf M.D., Director of Atlantic Health`s Metabolic Medicine and Weight
Control Center in Morristown, NJ. "It has a different mechanism of action than
other available formulations which will also prove to be a benefit."

Steven V. Joyal, Vice President of Scientific Affairs at Life Extension states:
"We are truly committed to maximizing the opportunity with oral Eligen® B12 (100
mcg) and other future products utilizing the Eligen® Technology. We pride
ourselves in bringing forward advanced nutritional supplements for our customers
and we believe that Eligen® B12 represents that type of innovative offering we
are always seeking."

Life Extension will have certain exclusivity in the USA for distribution via the
internet and also at specialty health food and nutritional retail outlets
including; The Vitamin Shoppe, GNC and Vitamin World. Oral Eligen® B12 (100mcg)
tablets will be available starting November of this year. Financial terms of the
agreement were not disclosed.

"This development and milestone represents a new day at Emisphere Technologies,"
emphasizes Novinski. "We are especially proud that our first commercial offering
will have the potential to revolutionize the nutritional field and bring great
benefit to people dependent on supplementing their natural Vitamin B12 levels."

Emisphere is also working on a high dose Medical Food Eligen® B12 product (1000
mcg) to compete directly with the standard high dose B12 injection currently
administered to millions of individuals under medical supervision for B12
deficiency. It is estimated that between 30 and 40 million high dose injections
of B12 are given each year in the US alone and over 250 million such injections
are given worldwide. Emisphere is currently conducting a clinical study with
Eligen® B12 (1000 mcg) which is expected to be completed in 2010.

Oral Eligen® B12 (100 mcg) and the foregoing statements have not been evaluated
by the Food and Drug Administration. Oral Eligen® B12 (100 mcg) is not intended
to diagnose, treat, cure, or prevent any disease.

About Vitamin B12

Vitamin B12 is necessary for the formation and maturation of red blood cells and
the synthesis of DNA. It is also necessary for normal nerve function and assists
in the body`s immune system. Unlike most vitamins, B12 is stored in the liver
until it is needed by the body. Deficiency is a major health concern that can
lead to anemia, fatigue, weakness, loss of appetite, neurological changes,
confusion and dementia.

Vitamin B12 is adequately absorbed in the bodies of healthy people, but many
older people lose their natural ability to absorb the nutrient. Younger
individuals may also have difficulty absorbing B12 as a result of taking certain
medications and chemotherapy. Those at highest risk for B12 deficiency include
anyone over age 60, those with GI tract disorders such as Crohn`s Disease,
Irritable Bowel Syndrome or Celiac Disease, individuals who have had bypass
surgery, those undergoing chronic therapy with absorption altering drugs,
alcoholics and vegetarians/vegans.

About Emisphere Technologies Inc.

Emisphere is a biopharmaceutical company that focuses on a unique and improved
delivery of therapeutic molecules or nutritional supplements using its
proprietary Eligen® Technology. The Eligen® Technology can be applied to the
oral route of administration as well as other delivery pathways such as buccal,
rectal, inhalation, intra-vaginal or transdermal. The company`s website is
www.emisphere.com.

About Life Extension

Life Extension has been offering consumers unique, scientifically innovative
nutraceuticals and supplements for over 29 years. They are a pioneer in the
nutraceutical field and a respected leader offering innovative products based on
research and science. The company`s website is www.lef.org.

Safe Harbor Statement Regarding Forward-Looking Statements

The statements in this release and oral statements made by representatives of
Emisphere relating to matters that are not historical facts (including without
limitation those regarding the timing or potential outcomes of research
collaborations or clinical trials, any market that might develop for any of
Emisphere's product candidates and the sufficiency of Emisphere's cash and other
capital resources) are forward-looking statements that involve risks and
uncertainties, including, but not limited to, the likelihood that future
research will prove successful, the likelihood that any product in the research
pipeline will receive regulatory approval in the United States or abroad, the
ability of Emisphere and/or its partners to develop, manufacture and
commercialize products using Emisphere's drug delivery technology, Emisphere's
ability to fund such efforts with or without partners, and other risks and
uncertainties detailed in Emisphere's filings with the Securities and Exchange
Commission, including those factors discussed under the caption "Risk Factors"
in Emisphere's Annual Report on Form 10-K for the fiscal year ended December 31,
2008, filed on March 16, 2009, and as amended on Form 10-K/A as filed on April
30, 2009, and our Quarterly Report on Form 10-Q for the quarter ended March 31,
2009, filed on May 7, 2009.

Media Relations:
West Mill Marketing Communications
Jeff Winton, 908-872-2682
jeffwmm@aol.com
or
Emisphere Technologies
Daria Palestina, 973-532-8002
dpalestina@emisphere.com
or
Investor Relations:
Rx Communications Group:
Paula Schwartz, 917-322-2216
pschwartz@rxir.com

Copyright Business Wire 2009